Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988 Feb;33(2):225-32.
doi: 10.1007/BF01535737.

Gastrointestinal damage induced by platelet-activating factor. Inhibition by the corticoid, dexamethasone

Affiliations

Gastrointestinal damage induced by platelet-activating factor. Inhibition by the corticoid, dexamethasone

J L Wallace et al. Dig Dis Sci. 1988 Feb.

Abstract

Intravenous infusion of platelet-activating factor (PAF-acether) induces extensive vasocongestion and damage in the stomach and small intestine of the rat. The effect of pretreatment with the corticoid dexamethasone (2 mg/kg) on such gastrointestinal damage in the rat has now been investigated, using macroscopic observation and the release of acid phosphatase, as an enzyme marker of cell disruption. Administration of PAF-acether (100 ng/kg/min intravenously, for 10 min) induced focal, intense hyperemia and hemorrhage in all the regions of the gastrointestinal tract, with the exception of the distal colon. This damage was associated with an increase in the release of acid phosphatase into the lumen of the stomach, duodenum, jejunum, and ileum following incubation in vitro. Pretreatment with dexamethasone reduced the macroscopically apparent gastrointestinal damage following PAF-acether administration and abolished the intraluminal release of acid phosphatase. Dexamethasone also significantly suppressed the hemoconcentration, as determined by changes in platelet and erythrocyte count and hematocrit, 30 min after PAF-acether infusion. Thus, as in endotoxin shock, this glucocorticoid can reduce the gastrointestinal damage associated with PAF-acether administration.

PubMed Disclaimer

References

    1. Eur J Pharmacol. 1985 Feb 26;109(2):257-61 - PubMed
    1. Eur J Pharmacol. 1985 Sep 10;115(1):45-52 - PubMed
    1. Am J Physiol. 1985 May;248(5 Pt 1):G580-6 - PubMed
    1. Clin Chest Med. 1982 Jan;3(1):121-32 - PubMed
    1. Eur J Pharmacol. 1980 Feb;61(4):347-53 - PubMed

Publication types